3 курс / Фармакология / Лечение_ВИЧ_инфекции,_К_Хоффман,_Дж_К_Роктрох,_Б_С_Кампс
.pdfЛечение ВИЧ-инфекции. 2005 год 535
20.Isaac A, Taylor S, Rubin G, et al. Lopinavir /ritonavir combined with twice daily indinavir: pharmacokinetics in blood, CSF and semen (the Protect Study). Abstract 531, 10th CROI 2003, Boston.
21.DHHS: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Retrieved April 14, 2004. http://www.amedeo.com/lit.php?id=11364535
22.Burger DM, Hugen PW, Kroon FP, et al. Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS 1998; 12: 2080-2. http://www.amedeo.com/lit.php?id=9814882
23.Hugen PWH, Burger DM, Brinkmann K, et al. Carbamazepine-indinavir interaction causes antiretroviral failure. Ann Pharmacother 2000;
34:465-70. http://www.amedeo.com/lit.php?id=10772431
24.Pratt CM, Mason J, Russell T. Cardiovascular safety of fexofenadine HCL. Am J Cardiol 1999; 84: 278-9. http://www.amedeo.com/lit.php?id=10335761
25.Abernethy DR, Barbey JT. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTprolongation. Clin Pharmacol Ther 2001; 69: 96-103. http://www.amedeo.com/lit.php?id=11240972
26.Michalets E: Update: Clinically Significant Cytochrome P-450 Drug Interaction. Ann Pharmacother 1998; 18: 84-112. http://www.amedeo.com/lit.php?id=9469685
27.Brinkmann K, Huysmans F, Burger DM. Pharmacokinetic interaction between Saquinavir and Cyclosporine. Ann Intern Med 1998; 129: 914-5. http://www.amedeo.com/lit.php?id=9867740
28.Piscitelli SC, Vogel S, Figg WD, et al. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficieny virus. Ann Pharmacother 1998; 18: 1212-6. http://www.amedeo.com/lit.php?id=9855318
29.Lanzafame M, Trevenzoli M, Faggian F, et al. Interaction between levothyroxine and indinavir in a patient with HIV infection. Infection 2002;
30:54-8. http://www.amedeo.com/lit.php?id=11876520
30.Centers for Disease Control and Prevention (CDC). Notice to Readers: Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR; 2004; 53: 37. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a4.htm
31.Merry C, Barry MG, Ryan M, et al. Interaction of sildefanil and indinavir when coadministered to HIV-positive patients. AIDS 1999; 13: 101- 7. http://www.amedeo.com/lit.php?id=10546851
32.Slain D, Amsden JR, Khakoo RA, et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Abstract A-1610, 43rd ICAAC 2003, Chicago.
Лечение ВИЧ-инфекции. 2005 год 539
Препараты |
Взаимодействия |
Рекомендации |
Ингибиторы |
|
|
фосфодиэстеразы |
|
|
Силденафил, тадалафил, |
Теоретически: ингибиторы фосфодиэстеразы ↑. |
Силденафил 25 мг каждые 48 ч |
варденафил (2, 25) |
Силденафил 100 мг + ритонавир 500 мг 2 раза в |
|
|
сутки: |
|
|
силденафил ↑ 1000% |
|
Заместительная терапия |
|
|
Метадон (36) |
Метадон ↓ 36% (Cmax 44% ↓) |
Следить за признаками абстинен- |
|
|
ции; при необходимости повысить |
|
|
дозу метадона |
Другие |
|
|
Атоваквон |
Теоретически: атоваквон ↓ |
При необходимости повысить дозу |
Дисульфирам (2) |
Жидкая форма Калетры содержит этанол и на |
Вместе не назначать |
|
фоне дисульфирама может вызвать рвоту |
|
Дексаметазон (2) |
Теоретически: лопинавир/ритонавир ↓ |
|
Метронидазол (2) |
Жидкая форма Калетры содержит этанол и на |
Вместе не назначать |
|
фоне метронидазола может вызвать рвоту |
|
Теофиллин (2) |
Теоретически: теофиллин ↓ |
МСК теофиллина |
|
|
|
Литература
1.Tseng A. www.tthhivclinic.com, General Hospital, Toronto, 2004.
2.Kaletra™, Abbott.
3.Bertz R, Lam W, Hsu A, et al. Assessment of the pharmacokinetic interaction between ABT-378/ritonavir and efavirenz in healthy volunteers and in HIV + subjects. Abstract 424, 40th ICAAC 2000, Toronto.
4.Bertz R, Foit C, Burt D, et al. Assessment of the Effect of Nevirapine on the Pharmacokinetics of Lopinavir/Ritonavir after Multiple Dosing in HIV-infected Adults. Abstract TUPEB4565, XIV Int AIDS Conf 2002, Barcelona.
5.Telzir™, GlaxoSmithKline.
6.Kashuba ADM, Tierey C, Downey GF, et al. Combining fosamprenavir, 908 with lopinavir/Ritonavir in HIV-1 infected adults in substantial reduction in Amprenavir and lopinavir concentrations: pharmakokinetic results from Adult ACTG Protocol A5143. Abstract H-855a , 43rd ICAAC 2003, Chicacgo.
7.Wire MB, Naderer OJ, Masterman AL, et al. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV10011 and APV 10012). Abstract 612, 11th CROI 2004, San Francisco. http://www.retroconference.org/2004/cd/PDFs/612.pdf
8.Corbett AH, Davidson L, Park JJ, et al. Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir, lopinavir and ritonavir. Abstract 611, 11th´CROI 2004, San Francisco.
9.Khanlou H, Graham E, Brill M, et al. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002; 16: 797-8. http://www.amedeo.com/lit.php?id=11964539
10.Bertz RJ, Foit C, Ashbrenner E, et al. Effect of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in HIV+ and healthy subjects. Abstract A1823, 42nd ICAAC 2002, San Diego.
11.Taburet AM, Raguin G, Le Tiec C, et al. Interaction between Amprenavir and lopinavir - ritonavir combination in heavily pretreated patients infected by HIV. Clin Pharmacol Ther 2004; 75: 310-23. http://www.amedeo.com/lit.php?id=15060509
12.Mauss S, Scholten S, Wolf E, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med 2004; 5: 15-7. http://www.amedeo.com/lit.php?id=14731164
13.Wynn Vezina HE, Brundage RC, Bushman L, et al. Pharmacologic management of the drug-drug interaction between lopinavir/ritonavir and amprenavir. Abstract 609, 11th CROI 2004, San Francicsco.
14.Kruse G, Stocker H, Breske A, et al. Trough levels of seven different Atazanavir regimes in HIV-infected patients. Abstract 6.6, 5th Int Worksh Clin Pharmacol HIV Ther 2004, Rome.
15.Tseng A, Phillips E, Antoniou A, et al. Steady-state pharmacokinetics and tolerability of indinavir when administered with lopinavir/r in anti- retroviral-experienced subjects. Abstract 8.10, 4th Int Worksh Clin Pharmacol HIV Ther 2003, Cannes.
16.Bertz R, Foit C, Ashbrenner E, et al. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. Abstract A1822, 42nd ICAAC 2002, San Diego.
17.Burger DM, Schmitz K, Schneider K, et al. Pharmacokinetics of lopinavir and reduced dose indinavir as a part of salvage therapy regimen. Abstract 8.2, 4th Int Worksh Clin Pharmacol HIV Ther 2003, Cannes.
18.Burger DM, Schmitz K, Schneider K, et al. Rescue therapy with indinavir 600 mg twice daily and lopinavir/ritonavir: baseline resistance, virologic response and pharmacokinetics. Abstract P170, 6th Int Congr Drug Ther HIV Inf 2002, Glasgow.
19.Isaac A, Taylor S, Rubin G, et al. Lopinavir /ritonavir combined with twice daily indinavir: pharmacokinetics in blood, CSF and semen (the Protect Study). Abstract 531, 10th CROI 2003, Boston.
20.La Porte CJ, Wasmuth JC, Schneider K, et al. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003; 17: 1700-2. http://www.amedeo.com/lit.php?id=12853756
21.Ribera E, Diaz M, Pou L, et al. Steady-state pharmacokinetics of double boosting regimen of lopinavir, plus minidose Ritonavir, plus Saquinavir soft-gel in HIV-infected adults. Abstract TUPE4545, XIV Int AIDS Conf 2002, Barcelona.
22.Staszewski S, Dauer B, Von Hentig N, et al. The LopSaq study: 24 week analysis of the double protease inhibitor salvage regimen containing lopinavir plus saquinavir without any additional antiretroviral therapy. Abstract 583, 2nd IAS Conference on HIV Pathogenesis and Treatment 2003, Paris.
540 Лекарственные взаимодействия
23.Stefan C, Von Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/Saquinavir. AIDS 2004; 18: 503-8. http://www.amedeo.com/lit.php?id=15090803
24.Klein C, Bertz R, Ashbrenner E, et al. Assessment of the multiple dose pharmacokinetic interaction of lopinavit/ritonavir with nelfinavir. Abstract 536, 10th CROI 2003, Boston.
25.Clinical Pharmacology, Gold Standard Multimedia, 2004. http://www.gsm.com
26.Michalets E. Update: Clinically Significant Cytochrome P-450 Drug Interaction. Ann Pharmacother 1998; 18: 84-112. http://www.amedeo.com/lit.php?id=9469685
27.Benedek ICH, Joshi A, Fiske WD, et al. Pharmacokinetic studies in healthy volunteers with efavirenz and the macrolide antibiotics, azithromycin and chlarithromycin. Abstract 347, 5th CROI 1998, Chicago.
28.Tseng AL, Foisy MM. Significant Interactions with New Antiretrovirals and Psychotropic Drugs. Ann Pharmacother 1999; 33: 461-73. http://www.amedeo.com/lit.php?id=10332538
29.Pratt CM, Mason J, Russell T. Cardiovascular safety of fexofenadine HCL. Am J Cardiol 1999; 84: 278-9. http://www.amedeo.com/lit.php?id=10335761
30.Abernethy DR, Barbey JT. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTprolongation. Clin Pharmacol Ther 2001; 69: 96-103. http://www.amedeo.com/lit.php?id=11240972
31.Rossi DR, Rathbun C, Slater LD. Symptomatic ortostasis with extended-release nifedipine and protease inhibitors. Ann Pharmacother 2002; 22: 1312-6. http://www.amedeo.com/lit.php?id=12389881
32.Fichtenbaum CJ, Gerber JG, Rosenkranz S. Pharmacokinetic interaction between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569-77. http://www.amedeo.com/lit.php?id=11873000
33.Carr RA, Andre AK, Bertz RJ, et al. Concomitant administration of ABT-378/ritonavir results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin. Abstract 1644, 40th ICAAC 2000, Toronto.
34.Doser N, Kubli S, Telenti A et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 2002; 16: 1982-3. http://www.amedeo.com/lit.php?id=12351967
35.Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the adult ACTG Cardiovascular Disease Focus Group. Clin Infec Dis 2000; 31: 121624. http://www.amedeo.com/lit.php?id=11073755
36.Antoniou T, Lin-in Tseng. Interactions between recreational drugs and antiretroviral agents. Annals Pharmacother 2002; 36: 1598-613. http://www.amedeo.com/lit.php?id=12243611
37.Centers for Disease Control and Prevention (CDC). Notice to Readers: Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR; 2004; 53: 37. http://www.amedeo.com/lit.php?id=11795500
38.Lam M, Ignoffo R, Meibohm B: Ein Leitfaden für klinisch-relevante Arzneimittel-Interaktionen in der Onkologie, Institute for Applied Healthcare Science.
39.Ghofrani HA, Olschewski H, Seeger W et al. Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure. Pneumologie. 2002; 56: 665-72. http://www.amedeo.com/lit.php?id=12442206
40.DICenzo R, Petersen D, Cruttenden K, et al. Effect of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults. Antimicrobial Agents and Chemotherapy 2004; 48: 4328-31. http://www.amedeo.com/lit.php?id=15504860
41.Breilh D, Rouzes A, Djabarouti S et al. Pharmacokinetic drug interaction of lopinavir/ritonavir in combination with tenofovir in experienced HIV+patients. Abstract A-445, 44th ICAAC 2004, Washington.
42.Kearney BP, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinaivr/ritonavir. Abstract A-1617, 43rd ICAAC 2003, Chicago. http://www.natap.org/2003/ICAAC/day5_2.htm
43.Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003, 9:954-60. http://amedeo.com/lit.php?id=12942457
44.Bertz RJ, Chiu YL, Naylor C et al. Lack of Effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. Abstract 201, 7th Int Congr Drug Ther HIV Inf 2004, Glasgow.
45.Negredo E, Moltó J, Burger D et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). JAIDS 2005; 38: 47-52. http://www.amedeo.com/lit.php?id=15608524
46.Langmann P, Winzer R, Nolte C, et al (2005). Efficacy and safety of ATV in combination with LPV/r. Abstract 56, 6th Int Worksh Clin Pharmacol HIV Ther 2005, Quebec.
47.Van der Lee MJ, Dawood L, ter Hofstede H, et al. The effect of lopinavir / ritonavir on the pharmacokinetic of lamotrigine in healthy subjects. Abstract 12, 6th Int Worksh Clin Pharmacol HIV Ther 2005, Quebec.
48.Faivre L, T. H., Vincent I, Abbara C, et al (2005). Potent drug interactions between tacrolismus and lopinavir / ritonavir therapy in HIVinfected liver transplant recipients. Abstract 26, 6th Int Worksh Clin Pharmacol HIV Ther 2005, Quebec.
49.Leith J, Walmsley S, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir alone or in combination with saquinavir, amprenavir, or lopinavir: interim analysis of BI1182.51. Abstract 34 , 5th Int Worksh Clin Pharmacol HIV-Ther 2004, Rome.
Лечение ВИЧ-инфекции. 2005 год 541
Невирапин
Вирамун™.
Одобренная доза: невирапин 200 мг 2 раза в сутки (вводный период: 200 мг 1 раз в сутки в первые 14 сут). В таблице подразумевается одобренная доза невирапина, если не указано иначе.
Метаболизм: невирапин инактивируется в основном CYP3A4, является индуктором CYP3A4 и 2B6 (1, 2).
Препараты |
Взаимодействия |
Рекомендации |
НИОТ |
Взаимодействия клинически не значимы (1) |
|
ННИОТ |
|
|
Эфавиренз (2, 4, 32) |
Эфавиренз 600 мг 1 раз в сутки + невирапин |
Нежелательная комбинация: сни- |
|
400 мг 1 раз в сутки (4): |
жается эффективность, повыша- |
|
эфавиренз ↓ 22% (Cmin 36% ↓) |
ется токсичность (32) |
ИП |
|
|
Атазанавир/ |
Возможно: атазанавир ↓ |
В настоящее время нет рекомен- |
ритонавир (2, 30) |
|
даций по изменению дозы атаза- |
|
|
навира |
Ампренавир (6, 7) |
Ампренавир/ритонавир 600/100 мг 2 раза в сутки |
МСК. |
|
+ невирапин: |
Ампренавир/ритонавир 450/200 мг |
|
ампренавир ↓ 35% (Cmin 20% ↓, Cmax 35% ↓) (6) |
2 раза в сутки (7) |
Фосампренавир (31) |
Фосампренавир/ритонавир 700/100 мг 2 раза в |
В этом исследовании коррекция |
|
сутки + невирапин: |
дозы не требовалась |
|
взаимодействия клинически не значимы |
|
Индинавир и индина- |
Индинавир/ритонавир 800/100 мг 2 раза в сутки + |
1) Индинавир: 1000 мг 3 раза в су- |
вир/ритонавир |
невирапин: |
тки (9). |
(8, 9, 10) |
индинавир: Cmin 57% |
2) Индинавир/ритонавир: |
|
ритонавир: Cmin 59% |
800/100 мг 2 раза в сутки (8). |
|
но индинавир > 100 нг/мл (8) |
Больным, которые получали лече- |
|
|
ние раньше, может потребоваться |
|
|
повышение дозы индинавира (8). |
|
|
Есть данные, что невирапин при |
|
|
приеме 1 раз в сутки снижает |
|
|
уровни индинавира/ритонавира |
|
|
больше, чем при приеме 2 раза в |
|
|
сутки (10) |
Лопинавир/ |
1) Лопинавир/ритонавир 400/100 + невирапин |
Лопинавир/ритонавир: 533/133 мг |
ритонавир (2, 5, 33, 34) |
200 мг 2 раза в сутки: у больных, которые полу- |
2 раза в сутки (2) |
|
чали лечение раньше, уровни лопинави- |
|
|
ра/ритонавира ↓ 27% (Cmin 51% ↓). |
|
|
2) Лопинавир/ритонавир 400/100 мг + невирапин |
|
|
200 мг 2 раза в сутки: (вирусная нагрузка < |
|
|
80 мл-1, n=31). |
|
|
Адекватная концентрация обоих препаратов (33) |
|
Нелфинавир (11, 12) |
Нелфинавир 750 мг 3 раза в сутки + невирапин: |
В этом исследовании коррекция |
|
нелфинавир ↑ 4%, Cmax 14% ↑ |
дозы не потребовалась |
Антиаритмические |
|
|
Амиодарон, бепридил, хини- |
Теоретически: антиаритмические ↓ |
При необходимости повысить дозу |
дин, флекаинид, лидокаин, |
|
антиаритмических средств |
пропафенон |
|
|
Антибиотики |
|
|
Кларитромицин, |
Кларитромицин 500 мг 2 раза в сутки + невира- |
Доза не меняется. |
эритромицин |
пин: |
Следить за показателями функции |
(1, 15) |
кларитромицин ↓ 35%, |
печени. |
|
активные метаболиты кларитромицина ↑ 58%, |
Теоретическая альтернатива: |
|
невирапин ↑ 26% |
азитромицин |
|
|
|
Антидепрессанты |
|
|
Нефазодон |
Теоретически: невирапин ↑ |
Вместе не назначать: |
|
|
гепатотоксичность |
542 Лекарственные взаимодействия
Препараты |
Взаимодействия |
Рекомендации |
Препараты зверобоя (2) |
Теоретически: невирапин ↓ |
Вместе не назначать |
Противосудорожные |
|
|
Карбамазепин, |
Теоретически: невирапин ↓ |
Вместе не назначать: |
фенитоин |
|
Теоретическая альтернатива: га- |
|
|
бапентин, ламотригин, вальпрое- |
|
|
вая кислота |
Противогрибковые |
|
|
Итраконазол, |
Теоретически: невирапин ↑, азолы ↓. |
МСК невирапина |
кетоконазол, |
Кетоконазол 400 мг 1 раз в сутки + невирапин |
|
флуконазол, |
(16): |
|
вориконазол (2, 16) |
кетоконазол ↓ 63% (Cmax 40% ↓), невирапин ↑ |
|
|
15-28%. |
|
|
Флуконазол + невирапин (2): |
|
|
невирапин ↑ 100%. |
|
|
Вориконазол: нет данных |
|
|
|
|
Гипотензивные |
|
|
Антагонисты кальция, в ча- |
|
|
стности амлодипин, фелоди- |
Теоретически: |
При необходимости повысить дозу |
пин, нифедипин, верапамил |
антагонисты кальция ↓ |
антагонистов кальция |
Босентан (3, 26) |
Теоретически: невирапин ↓ |
Для лечения легочной гипертен- |
|
|
зии применяется силденафил |
|
|
(официально не одобрен) |
Противотуберкулезные |
|
|
Рифабутин (21, 22) |
|
Коррекция дозы не требуется |
Рифампицин (22-25) |
Невирапин (Cmin 68% ↓) |
Вместе не назначать |
Противоопухолевые |
|
|
Циклофосфамид (3) |
Теоретически: нейротоксичные метаболиты ↑ |
Не назначать с 2 и более нейро- |
|
|
токсичными препаратами |
Наркотики |
|
|
Кокаин (18) |
Теоретически: норкокаин ↑ |
Вместе не назначать |
|
(гепатотоксичность) |
|
|
|
|
Препараты для лечения |
|
|
гастрита и язвы желудка |
|
|
Циметидин |
Теоретически: невирапин ↑ |
Теоретическая альтернатива: фа- |
|
|
мотидин, низатидин, ранитидин |
Снотворные |
|
|
Барбексаклон, |
Теоретически: невирапин ↓ |
|
фенобарбитал |
|
|
Бензодиазепины, в частно- |
Теоретически: бензодиазепины ↓ |
Теоретическая альтернатива: ло- |
сти диазепам, мидазолам, |
|
разепам, оксазепам, темазепам |
триазолам, золпидем |
|
|
Иммунодепрессанты |
|
|
Циклоспорин, сиролимус, |
Теоретически: иммунодепрессанты ↓ |
Скорректировать дозу иммуноде- |
такролимус |
|
прессантов по данным МСК |
Гиполипидемические |
|
|
Аторвастатин, |
Теоретически: статины ↓ |
Теоретическая альтернатива: пра- |
ловастатин, |
|
вастатин |
симвастатин (1, 15, 16) |
|
|
|
|
|
Пероральные |
Этинилэстрадиол 0,035 + норэтистерон 1,0: |
Использовать дополнительный |
контрацептивы b(17) |
этинилэстрадиол ↓ 29%, |
вид контрацепции |
|
норэтистерон ↓ 18% |
|
Ингибиторы |
|
|
фосфодиэестеразы |
|
|
Силденафил, |
Теоретически: уровни ингибиторов фосфодиэ- |
Внимание: в каждом случае под- |
|
стеразы ↓ |
бирать дозу индивидуально |
Лечение ВИЧ-инфекции. 2005 год 543
Препараты |
Взаимодействия |
Рекомендации |
тадалафил, варденафил |
|
|
Заместительная терапия |
|
|
Метадон (2, 19, 20) |
Метадон ↓ через 4-10 сут: абстинентный синдром |
Повышать дозу метадона по 10 мг |
|
|
за раз |
Другие препараты |
|
|
Дексаметазон |
Теоретически: невирапин ↓ |
|
Сульфаметоксазол |
Сыпь ↑ |
|
Варфарин (27) |
Варфарин ↓ ↑ |
Следить за МНО |
Литература
1.Tseng A. www.tthhivclinic.com, General Hospital, Toronto, 2004.
2.Viramune, Boehringer Ingelheim.
3.Clinical Pharmacology, Gold Standard Multimedia, 2004. http://www.gsm.com
4.Veldkamp AI, Harris M, Montaner JSG, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in HIV type 1 infected persons. J Infect Dis 2001; 184: 37-42. http://www.amedeo.com/lit.php?id=11398107
5.Kaletra™, Abbott.
6.Goujard C, Meynard JL, Choudet N, et al. Steady-state pharmacokinetics of amprenavir 600 mg BID and ritonavir 100 mg BID with or without NNRTI in HIV-1 infected patients. Abstract P268, 5th Int Congr Drug Ther HIV Inf 2000, Glasgow. http://www.aegis.com/conferences/hiv5/P268.html
7.Degen O, Kurowski M, van Lunzen J, et al. Amprenavir and ritonavir: intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients. Abstract 739, 8th CROI 2001, Chicago. http://www.retroconference.org/2001/abstracts/abstracts/abstracts/739.htm
8.Burger DM, Prins JM, van der Ende ME, et al. The effect of nevirapine on the pharmakokinetics of indinavir/ritonavir 800/100 mg BID. JAIDS 2004; 35: 97-8. http://www.amedeo.com/lit.php?id=14707800
9.Murphy R, Gagnier P, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients. Abstract 374, 4th CROI 1997, Washington.
10.Crommentuyn KML, van Heeswijk RPG, Veldkamp AI, et al. Nevirapine once daily versus twice daily: implications for drug-drug interactions. Abstract 1.11, 2nd Int Worksh Clin Pharmacol HIV Ther 2001, Noordwijk.
11.Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and Nevirapine. AIDS 1998; 12: 1243-4. http://www.amedeo.com/lit.php?id=9677174
12.Vilaro J, Mascaro J, Colomer J, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine in HIV-positive patients. Abstract A497, 41st ICAAC 2001, Chicago.
13.Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP). Abstract 376, 4th National CROI 1997, Washington.
14.Sabo J, MacGregor T, Lamson M, et al. Pharmacokinetics of tipranavir and nevirapine. Abstract 249, 10th Annual Canadian Conference on HIV/AIDS Research 2001, Toronto.
15.Robinson P, Gigliotti M, Lamson M, et al. Effect of the reverse transcriptase inhibitor nevirapine, on the steady-state pharmacokinetics of clarithromycin in HIV positive patients. Abstract 374, 6th CROI 1999, Chicago.
16.Lamson M, Robinson P, Gigliotti M, et al. The pharmacokinetic interactions of nevirapine and ketoconazol. Abstract 12218, 12th World AIDS Conference 1998, Geneva.
17.Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when admnistered concurrently to HIV-infected women. Journal of the Acquired Immune Deficiency Syndrome 2002; 29: 471-7. http://www.amedeo.com/lit.php?id=11981363
18.Antoniou T, Lin-in Tseng. Interactions between Recreational Drugs and antiretroviral agents. Ann Pharmacother 2002; 36: 1598-613. http://www.amedeo.com/lit.php?id=12243611
19.Altice FL, Friedland GH, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadon. AIDS 1999; 13: 957-62. http://www.amedeo.com/lit.php?id=10371177
20.Clarke S, Mulcahy F, Back D, et al. Managing methadone and non-nucleoside reverse transcriptase inhibitors: guidelines for clinical practise. Abstract 88, 7th CROI 2000, San Francisco.
21.Maldonaldo S, Lamson M, Gigliotti M, et al. Pharmacokinetic interaction between nevirapine and rifabutin. Abstract 341, 39th ICAAC 1999, San Francisco.
22.Centers for Disease Control and Prevention (CDC). Notice to Readers: Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR; 2004; 53: 37. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a4.htm
23.Robinson P, Lamson M, Gigliotti M, et al. Pharmacokinetic interaction between nevirapine and rifampin. Abstract 60623, 12th World AIDS Conference 1998, Geneva.
24.Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. JAIDS 2001; 28: 450-3. http://www.amedeo.com/lit.php?id=11744833
25.Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis (letter). AIDS 2003; 17: 637-8. http://www.amedeo.com/lit.php?id=12598789
26.Ghofrani HA, Olschewski H, Seeger W, et al. Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure. Pneumologie 2002; 56: 665-72. http://www.amedeo.com/lit.php?id=12442206
27.Dioniso D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 2001; 15: 277-8. http//www.amedeo.com/lit.php?id=11216940
28.Tripranavir Investigators Broschüre, Boehringer Ingelheim, 2004.
544 Лекарственные взаимодействия
29.Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions among antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999; 36: 289-304. http://www.amedeo.com/lit.php?id=10320951
30.Alexander CS, Montaner JG, Langridge S, et al. Interaction between atazanavir/Ritonavir (ATV/r) and nevirapine (NVP) is observed in a clinical setting. Abstract P275, 7th Int Congr Drug Ther HIV Inf 2004, Glasgow.
31.DeJesus E, Piliero P, Summers K, et al. Evaluation of the pharmacokinetik drug interaction between fosamprenavir (FPV), FPV plus ritonavir (RTV) and nevirapine (NVP) in HIV-infected patients (APV10014). Abstract A-447, 44th ICAAC 2004, Washington.
32.van Leth F., Hassink E., Phanuphak P. et al. Results of the 2NN Study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either NVP alone, эфавиренз alone or both drugs combined, together with stavudine and lamivudine. Abstract 176, 10th CROI 2003.
33.Bertz R, Foit C, Burt D, et al. Assessment of the effect of nevirapine on the pharmacokinetics of lopinavir/ritonavir after multiple dosing in HIV-infected adults. Abstract TUPEB4565, XIV Int AIDS Conf 2002, Barcelona.
34.Negredo E, Moltó J, Burger D et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). JAIDS 2005; 38: 47-52. http://www.amedeo.com/lit.php?id=15608524